Lung Neoplasms
Conditions
Keywords
Lung Neoplasms, diffusion weighted MRI, ADC value, treatment effect
Brief summary
The purpose of this study is to investigate the diagnostic accuracy of ADC value of diffusion weighted MRI in comparison of conventional treatment assessment criteria in evaluation of chemotherapy. Moreover, the investigators aim to clarify the correlation of ADC value with histologic type and grade of lung cancer and survival of patients.
Detailed description
In recent years, lung cancer is an aggressive and heterogeneous disease, Advances in surgical and chemotherapeutic approaches have been made, but the long-term survival rate remains low. Although effective mass screening of high-risk groups could potentially be of benefit, randomized trials of screening with the use of chest radiography with or without cytological analysis of sputum specimens have shown no reduction in lung-cancer mortality. Currently, Response Evaluation Criteria in Solid Tumors (RECIST) by CT is the most commonly used to evaluate chemotherapy of lung cancer patient, but patients have to be exposed to radiation. For this reason, the investigators aim to assess the diagnostic accuracy of apparent diffusion coefficient (ADC) value, a specific parameter of radiation-free diffusion weighted MRI, in comparison of RECIST, and its correlation with histologic type and grade of lung cancer as well. Furthermore, the investigators investigate its correlation with Progression Free Survival (PFS) and Overall Survival (OS) in patients.
Interventions
PROCEDUREDiffusion Magnetic Resonance Imaging
Diffusion weighted imaging (DWI) is a form of magnetic resonance imaging based upon measuring the random Brownian motion of water molecules within a voxel of tissue. The relationship between histology and diffusion is complex, however generally densely cellular tissues or those with cellular swelling exhibit lower diffusion coefficients, and thus diffusion is particularly useful in tumour characterisation
Sponsors
Air Force Military Medical University, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age: 18-75 2. Patients have confirmed lung cancer by histopathological methods (fiber, bronchoscopy, lung biopsy, open chest biopsy, pleural effusion exfoliated cells, sputum exfoliated cells) 3. After clinical assessment, patients who need chemotherapy (tumor stage III or IV of lung cancer or others who are reluctant to receive pneumonectomy); 4. Patients have no previous history of chemotherapy 5. Patients with at least one clearly measurable lung lesion (lesion size larger than 10mm, by spiral CT, according to RECIST) 6. Health status scoring between 0-2 by Eastern Cooperative Oncology Group(ECOG) method 7. Patients voluntarily to join this study and signed informed consents.
Exclusion criteria
1. Any body metal implants (pacemaker implantation, nerve stimulator, vascular stent, aneurysm clip, eye foreign body, the inner metal prosthesis) or artificial heart valves 2. Patients with claustrophobia to MRI or CT examination 3. Patients who are reluctant to comply with follow-up and subsequent examination 4. The other condition that do not meet the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in ADC value | 4,8,12 weeks post initial chemotherapy | Change from baseline in ADC value in 4,8,12 weeks(every two cycles of chemotherapy) post initial treatment when compared with RECIST (based on the CT examination), thus it can be estimated that the accuracy of ADC value in evaluating chemotherapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ADC value | 1 day before initial chemotherapy | The correlation of ADC value in 1 day before initial chemotherapy with histologic type and grade of lung cancer |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in ADC value | At the date of first documented progression, assessed up to 12 months | Change from baseline in ADC value will be documented at date of first documented progression, assessed up to 12 months post initial chemotherapy. |
Countries
China
Contacts
Primary ContactLi Jie, master
Outcome results
None listed